David Melnick Net Worth

David Melnick biography

Dr. David Melnick M.D. serves as Cheif Medical Officer of the Company. Dr. Melnick Prior to joining Spero, Dr. Melnick served as Vice President of Clinical Development for Anti-Infectives at Allergan since 2015. In that capacity, he oversaw the development and regulatory approval of Teflaro®, Avycaz®, and Dalvance® in the United States. Prior to Allergan, Dr. Melnick served fifteen years at AstraZeneca in various levels of increasing responsibility, most recently as Vice President of Clinical Development for Anti-Infectives. In that capacity, he oversaw the late stage clinical development of Merrem®, Teflaro®, and Avycaz®. In addition, he served as the acting Vice President for early development at AstraZeneca. He received his medical training at Columbia University, followed by a Residency in Internal Medicine at The New York Hospital-Cornell Medical Center. Following a Fellowship in Infectious Disease at Yale University, he held faculty positions at the Boston University School of Medicine and the National Institute of Allergy and Infectious Diseases. He subsequently joined Kaiser-Permanente as a practicing Infectious Diseases specialist and as the Director of HIV Clinical Research at Kaiser Permanente Mid-Atlantic, with a faculty appointment at Georgetown University.

What is the salary of David Melnick?

As the Cheif Medical Officer of Spero Therapeutics Inc, the total compensation of David Melnick at Spero Therapeutics Inc is $936,289. There are 3 executives at Spero Therapeutics Inc getting paid more, with Ankit Mahadevia having the highest compensation of $1,785,680.

How old is David Melnick?

David Melnick is 68, he's been the Cheif Medical Officer of Spero Therapeutics Inc since 2018. There are 1 older and 18 younger executives at Spero Therapeutics Inc. The oldest executive at Spero Therapeutics Inc is Dr. David A. Melnick M.D., 69, who is the Chief Medical Officer.

What's David Melnick's mailing address?

David's mailing address filed with the SEC is C/O SPERO THERAPEUTICS, INC., 675 MASSACHUSETTS AVENUE, 14TH FLOOR, CAMBRIDGE, MA, 02139.

Insiders trading at Spero Therapeutics Inc

Over the last 15 years, insiders at Spero Therapeutics Inc have traded over $15,920,732 worth of Spero Therapeutics Inc stock and bought 3,223,281 units worth $44,767,755 . The most active insiders traders include Plc Gsk, Jean Francois Formela és Capital Management, Llc Aqu.... On average, Spero Therapeutics Inc executives and independent directors trade stock every 71 days with the average trade being worth of $122,858. The most recent stock trade was executed by Ankit Mahadevia on 27 August 2024, trading 5,912 units of SPRO stock currently worth $7,981.

What does Spero Therapeutics Inc do?

spero therapeutics is focused on the development of novel therapies to treat highly resistant bacterial infections. the culture at spero is one of respect, action, collaboration and transparency. spero team members are leaders in the field, and have the ability and desire to be a part of a team. at spero, a feeling that we are part of something groundbreaking and innovative fuels our approach.

Spero Therapeutics Inc executives and stock owners

Spero Therapeutics Inc executives and other stock owners filed with the SEC include:

• Ankit Mahadevia,
  President, Chief Executive Officer, Director
• Dr. Ankit Mahadevia M.D., MBA,
  Co-Founder, CEO, Pres & Director
• Cristina Larkin,
  Chief Operating Officer and Chief Commercial Officer
• David Melnick,
  Cheif Medical Officer
• Dr. David A. Melnick M.D.,
  Chief Medical Officer
• Cristina Larkin,
  Chief Operating Officer
• Thomas Parr,
  Chief Scientific Officer
• Cynthia Smith,
  Independent Director
• Milind Deshpande,
  Independent Chairman of the Board
• Frank Thomas,
  Independent Director
• Patrick Vink,
  Independent Director
• John Pottage,
  Independent Director
• Jean-Francois Formela,
  Independent Director
• Sharon Klahre,
  IR Contact Officer
• Scott Jackson,
  Independent Director
• Timothy Keutzer,
  Chief Development Officer
• Stephen DiPalma,
  Chief Financial Officer, Treasurer
• Timothy Keutzer,
  Chief Devel. Officer
• James P. Brady,
  Chief Human Resource Officer
• David Musselman,
  Sr. VP of Sales & Market Access
• Tamara Lynn Joseph L.L.M., J.D.,
  Chief Legal Officer
• Ted Jenkins,
  VP & Head of Investor Relations
• Dr. Thomas R. Parr Jr., Ph.D.,
  Chief Scientific Officer
• Satyavrat Shukla C.F.A.,
  Chief Financial Officer
• David P Southwell,
  Director
• John J Gorman,
  Director
• Jack Fingerhut,
  President
• Allen S Greene,
  Chairman of the Board and CEO
• Lager H Martin,
  Director
• Joel Sendek,
  Chief Financial Officer
• Plc Gsk,
  10% owner
• Joseph R Fish,
  EVP & Chief Technology Officer
• Leonard J Stanley,
  Director
• Vikas Goyal,
  Director
• Casper Breum,
  Director
• Stanley P Wirtheim,
  Chief Financial Officer
• Zohar Ben Dov,
  10% owner
• Esther Rajavelu,
  See Remarks
• Capital Management, Llc Aqu...,
  
• Kathleen Tregoning,
  
• Kamal Hamed,
  Chief Medical Officer
• Sath Shukla,
  CEO & President
• Tamara L Joseph,
  Chief Legal Officer